LYTIR

Company · SUPN

Supernus Pharmaceuticals, Inc.

In the 12 months to Nov 19, 2026: 1 filing by holders of 5% or more; 2 congressional trade disclosures.

All insider filings at the SEC

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Integrated Core Strategies (US) LLC filed Aug 6, 2026 Schedule 13G/A passive filing 6.6%

Congress · STOCK Act

The Althing

Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.

  1. Gilbert Cisneros (D-CA31): Purchase Mar 3, 2026 reported Apr 7, 2026 one of 141 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  2. Gilbert Cisneros (D-CA31): Purchase Dec 11, 2025 reported Jan 12, 2026 one of 121 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000

Executive branch · OGE Form 278-T

Reported by the President

2 confirmed trades on scanned reports whose security name matches this company's own filed name exactly (letter case, punctuation and Inc/Corp-style endings aside). All of Donald J. Trump's reports

  1. Sale: SUPERNUS PHARMACEUTICALS Jul 29, 2026 reported Sep 8, 2026 President Donald J. Trump Periodic Transaction Report 09.08.26 $15,001 – $50,000
  2. Sale: SUPERNUS PHARMACEUTICALS May 15, 2026 reported Jun 25, 2026 President Donald J. Trump Periodic Transaction Report 06.25.26 (2) $15,001 – $50,000

Lobbying · Senate LDA reports

Lobbying filed

2 quarterly lobbying reports for 2026 naming Supernus Pharmaceuticals, Inc. as the client: 2 by outside firms it hired. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.

  1. JEFFREY J. KIMBELL & ASSOCIATES, INC. Q2 2026 filing $20K
  2. JEFFREY J. KIMBELL & ASSOCIATES, INC. Q1 2026 filing $20K

Sources: SEC EDGAR (Forms 4 and 144), Senate LDA lobbying reports, OGE Form 278-T reports on whitehouse.gov and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.